Longeveron (LGVN) Non-Current Deferred Tax Liability (2022 - 2023)
Longeveron (LGVN) recorded quarterly Non-Current Deferred Tax Liability of $391000.0 in Q4 2023, down 3.69% quarter-over-quarter from $406000.0 in Q4 2022, and down 3.69% on a YoY basis from $406000.0 in Q4 2022.
Longeveron (LGVN) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Longeveron's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $391000.0 for Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability fell 3.69% year-over-year to $391000.0; the TTM figure through Dec 2023 stood at $391000.0 (down 3.69% YoY), while the FY2023 annual figure was $391000.0, down 3.69% from the prior year.
- Non-Current Deferred Tax Liability was $391000.0 for Q4 2023 at Longeveron, down from $406000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $406000.0 in Q4 2022 to a low of $391000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 391,000.00 |
| Dec 31, 2023 | 391,000.00 |
| Dec 31, 2022 | 406,000.00 |
| Dec 31, 2022 | 406,000.00 |